Osteoporosis becomes much more common after menopause because falling estrogen levels accelerate bone loss. But treatment is not the same for every postmenopausal woman. Some women may need mainly lifestyle measures and monitoring, while others need medication to reduce the risk of hip, spinal or other fragility fractures.
The most appropriate treatment depends on:
- Bone mineral density
- Whether a fragility fracture has already occurred
- Age
- Overall fracture risk
- How recently a fracture occurred
- Kidney function
- Other medical conditions
- Previous osteoporosis treatment
- How well a woman can tolerate or follow a particular treatment
For a broader overview of osteoporosis, diagnosis and available therapies, see our main guide to Osteoporosis Treatment.
Why Does Osteoporosis Become More Important After Menopause?
Estrogen helps regulate the normal cycle in which old bone is removed and new bone is formed. When estrogen levels fall during and after menopause, bone breakdown can temporarily increase faster than bone formation.
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
As a result, women may lose bone more rapidly during the years around menopause. Over time, the combination of hormonal bone loss and ageing can make the skeleton weaker and more vulnerable to fractures. Common osteoporosis-related fracture sites include:
- Spine
- Hip
- Wrist
- Upper arm
However, menopause alone does not mean a woman automatically needs osteoporosis medication. The treatment decision is based on how likely she is to fracture.
How Do Doctors Decide Whether Treatment Is Needed?
Doctors generally look beyond one bone-density number. Assessment may include:
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
- A DXA or DEXA bone-density scan
- A history of previous fractures
- Age
- Family history of hip fracture
- Body weight
- Smoking and alcohol use
- Long-term steroid treatment
- Other medical conditions
- Falls risk
Current osteoporosis guidelines generally divide patients into broad groups such as:
| Fracture Risk | Typical Treatment Direction |
|---|---|
| Lower risk | Lifestyle measures, correction of deficiencies and monitoring may be sufficient |
| High risk | Osteoporosis medication is generally recommended |
| Very high risk | Specialist assessment and bone-building treatment may be considered first |
Who Is Considered at High Fracture Risk?
A woman may be considered at high risk because of factors such as:
- Osteoporosis-range bone density
- A previous fragility fracture
- Advanced age combined with other risk factors
- Long-term glucocorticoid treatment
- A high calculated fracture probability
What Does “Very High Fracture Risk” Mean?
Very high fracture risk generally refers to women whose chance of another serious fracture is substantially greater than average. Examples may include women with:
- Multiple vertebral fractures
- A recent vertebral fracture
- Very low bone density combined with fractures
- Fractures despite osteoporosis treatment
- Several major fracture-risk factors occurring together
For many high-risk women, treatment starts by slowing bone loss. For some very-high-risk women, treatment may start by actively building new bone.
1. Bisphosphonates: Common First-Line Treatment
Bisphosphonates are among the most widely used osteoporosis treatments for postmenopausal women. They reduce the activity of osteoclasts—the cells responsible for breaking down bone. This slows bone loss and helps reduce fracture risk. Common options include:
- Alendronate
- Risedronate
- Zoledronic acid
- Ibandronate in selected situations
2. Bone-Building Treatment for Very High-Risk Women
Some postmenopausal women need a different approach. If fracture risk is very high, particularly when serious vertebral fractures have already occurred, current guidelines support considering an anabolic-first strategy.
Why Starting With Bone-Building Treatment Can Matter
Treatment order is becoming increasingly important in osteoporosis care. In very-high-risk women, research shows that certain bone-building treatments can reduce fractures more effectively than beginning with some traditional antiresorptive therapies.
3. Hormone Replacement Therapy After Menopause
Because estrogen loss contributes to postmenopausal bone loss, hormone replacement therapy (HRT) can help maintain bone density and reduce fracture risk. However, HRT is not automatically the first osteoporosis treatment for every postmenopausal woman.
Its role depends strongly on:
- Age
- Time since menopause
- Menopausal symptoms
- Breast cancer risk
- Blood clot risk
- Cardiovascular history
One important recent development is that the 2024 NOGG guideline recommends considering HRT as a first-line treatment option for younger postmenopausal women aged 60 or younger who have high fracture risk and a low baseline risk of malignant and thromboembolic complications.
Is HRT Better Than Bisphosphonates?
Not generally. HRT may be particularly attractive in a younger postmenopausal woman who:
- Has osteoporosis or increased fracture risk
- Also has troublesome menopausal symptoms
- Has no important contraindications
What Is the Best Osteoporosis Treatment After Menopause?
| Clinical Situation | Possible Treatment Approach |
|---|---|
| High fracture risk | Oral bisphosphonate or IV zoledronate commonly used first-line |
| Bisphosphonate unsuitable or not tolerated | Denosumab or another appropriate alternative may be considered |
| Very high fracture risk with severe or multiple vertebral fractures | Consider anabolic treatment such as teriparatide, abaloparatide or romosozumab |
| Younger postmenopausal woman with high fracture risk and suitable risk profile | HRT may be considered |
| Need mainly vertebral-fracture protection and other therapies unsuitable | Raloxifene may be considered in selected women |
| Recent hip fracture | Prompt osteoporosis treatment; IV zoledronate is one guideline-supported first-line option |
What About Calcium After Menopause?
Postmenopausal women need adequate calcium because calcium is an important structural component of bone. Food sources are generally preferred when possible. These may include:
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
- Milk
- Yoghurt
- Cheese
- Calcium-fortified foods
- Other calcium-rich foods appropriate to the individual's diet
Does Vitamin D Treat Postmenopausal Osteoporosis?
Vitamin D helps the body absorb calcium and is necessary for normal bone mineralisation. Women should have adequate vitamin D, particularly when receiving osteoporosis medication. Vitamin D supplementation may be recommended if:
- A deficiency is present
- Dietary intake is inadequate
- Sunlight exposure is limited
- The woman is housebound
- Malabsorption is present
Can Osteopenia After Menopause Require Treatment?
Yes. Osteopenia does not automatically mean “no treatment needed.” A woman whose bone density is in the osteopenia range may still have a high fracture risk because of:
- Previous fragility fracture
- Advanced age
- Long-term steroid use
- High FRAX probability
- Multiple clinical risk factors
What Is a Bisphosphonate Drug Holiday?
Because bisphosphonates remain in bone for a long time, selected women who become low-to-moderate risk after several years of treatment may be considered for a temporary break. This is called a bisphosphonate holiday. It is not appropriate for everyone.
Women who remain at high risk—particularly those who:
- Are older
- Have had hip or vertebral fractures
- Have very low bone density
- Develop another fracture during treatment
Can Postmenopausal Osteoporosis Be Reversed?
Bone density can improve with effective treatment, and fracture risk can fall substantially. Bone-building therapies can produce particularly meaningful increases in bone density in appropriately selected women.
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
However, osteoporosis is usually managed as a long-term condition rather than considered permanently cured. Existing spinal deformity or damage from a previous fracture cannot simply be reversed by increasing bone density. The main goal is to prevent the next fracture.
A Simple Treatment Pathway for Postmenopausal Osteoporosis
| Step | What Usually Happens |
|---|---|
| 1. Assess fracture risk | Review fractures, clinical risk factors, DXA and FRAX when appropriate |
| 2. Correct reversible problems | Address vitamin D deficiency, low calcium intake and secondary causes |
| 3. High fracture risk | Start antiresorptive treatment such as a bisphosphonate; alternatives depend on suitability |
| 4. Very high fracture risk | Consider specialist anabolic-first treatment |
| 5. Protect treatment gains | Follow anabolic therapy with an antiresorptive medicine |
| 6. Monitor long term | Review fractures, bone density, adherence, side effects and continuing risk |
The Bottom Line
Osteoporosis treatment for postmenopausal women should be based on fracture risk rather than menopause or bone density alone. For many women at high fracture risk, oral bisphosphonates such as alendronate or risedronate, or intravenous zoledronate, are appropriate first-line treatments.
Calcium, vitamin D, strength exercise and fall prevention remain important throughout treatment, but they should not replace osteoporosis medication when fracture risk is sufficiently high.
Most importantly: The best treatment after menopause is not simply the strongest osteoporosis medicine. It is the treatment sequence that matches the woman's current fracture risk, medical history and long-term needs while providing the best realistic chance of preventing her next fracture.
